Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced that its wholly-owned drug discovery subsidiary, ReceptoPharm, in collaboration with Soochow University in China has published strong...
Nutra Pharma Announces Publication Of Positive Results Of ReceptoPharm Arthritis Study
New Surgical Option For Wrist Arthritis
Breaking a fall, such as a tumble on the sidewalk, with your hands and wrists is everyone’s natural reflex. But, if you fall hard enough, you’ll often fracture your radius bone, or even one of the smaller wrist bones and wrist ligaments. Left untreated, these injuries could lead to disabling...
Nutra Pharma Subsidiary, ReceptoPharm, Files Patent Application For Novel Treatment Of Arthritis Using RPI-78
Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that its wholly-owned drug discovery subsidiary, ReceptoPharm, has filed a patent application with the United States Patent and...
Stanford Develops Imaging Technique To Catch Arthritis Early In Onset
You come into a doctor’s office with severe knee pain. The physician orders an MRI, which reveals substantial loss of cartilage-osteoarthritis, that is-in your knee joint. At this point, not much can be done beyond gulping down palliatives and trying to keep your weight off the joint. But the damage...
Savient Announces FDA’s Advisory Panel To Review Pegloticase For Treatment Failure Gout Patients
Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced that its biologics license application (BLA) for pegloticase for treatment-failure gout will be reviewed by the Arthritis Advisory Committee appointed by the U.S. Food and Drug Administration (FDA) on March 5, 2009 as required for a drug of a new...
Can-Fite Completed Patient Enrollment For The Confirmatory Phase IIb Trial In Rheumatoid Arthritis Patients With CF101
Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange has achieved yet another goal by completion of enrollment of 230 patients in its confirmatory phase IIb RA trial. Approximately 230 patients were enrolled to this study, randomized into 3 groups treated with...
Phase III Study Showed Rituxan® Decreased The Progression Of Joint Damage In Patients With Early Rheumatoid Arthritis
Genentech, Inc. (NYSE:DNA) and Biogen Idec (Nasdaq:BIIB) announced today that a Phase III clinical study of Rituxan® (rituximab) in patients with early rheumatoid arthritis (RA) who have not previously been treated with methotrexate (MTX) met its primary endpoint. In this study, known as IMAGE, patients...
Phase III Study Showed Rituxan® Decreased The Progression Of Joint Damage In Patients With Early Rheumatoid Arthritis (RA)
Genentech, Inc. (NYSE: DNA) and Biogen Idec (Nasdaq: BIIB) announced that a Phase III clinical study of Rituxan® (rituximab) in patients with early rheumatoid arthritis (RA) who have not previously been treated with methotrexate (MTX) met its primary endpoint. In this study, known as IMAGE, patients...
MabThera Inhibits The Destruction Of Joints In Patients With Early Rheumatoid Arthritis
Roche announced recently that MabThera (rituximab) can significantly inhibit structural damage to joints in patients with early rheumatoid arthritis (RA) who have not been treated with methotrexate (MTX), the current standard of care for RA treatment. Results from the IMAGE1 study showed that at one...
Better Management More Important Than New Drugs For Arthritis
Although there has been an increase in the number of new arthritis treatments in recent years, the best results will come from more effective use of the drugs we have. Research published in BioMed Central’s open access journal Arthritis Research and Therapy investigates the effectiveness of available...